Clinical Trial Update: Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacokinetics and receptor occupancy of BMS-984923 in Alzheimer's disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-984923

Snippet

Sponsor: Yale University | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED | Results posted: 2023-04-13